• 1
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 75967.
  • 2
    Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989; 59: 5219.
  • 3
    Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 78791.
  • 4
    Chadeneau C, Hay K, Hirte HW, Gallinger S, Baccetti S. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res 1995; 55: 25336.
  • 5
    Tahara H, Kuniyasu H, Yokozaki H, Yasui W, Shay JW, Ide T, Tahara E. Telomerase activity in preneoplastic and neoplastistic gastric and colorectal lesions. Clin Cancer Res 1995; 1: 124551.
  • 6
    Engelhardt M, Drullinsky P, Guillem J, Moore MA. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res 1997; 3: 193141.
  • 7
    Tang R, Cheng AJ, Wang JY, Wang TC. Close correlation between telomerase expression and adenomatous polyp progression in multistep colorectal carcinogenesis. Cancer Res 1998; 58: 40524.
  • 8
    Chadeneau C, Hay K, Hirte HW, Gallinger S, Bacchetti S. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res 1995; 55: 25336.
  • 9
    Niiyama H, Mizumoto K, Sato N, Nagai E, Mibu R, Fukui T, Kinoshita M, Tanaka M. Quantitative analysis of hTERT mRNA expression in colorectal cancer. Am J Gastroenterol 2001; 96: 18951900.
    Direct Link:
  • 10
    Boldrini L, Faviana P, Gisfredi S, Zucconi Y, Di Quirico D, Donati V, Berti P, Spisni R, Galleri D, Materazzi G, Basolo F, Miccoli P, et al. Evaluation of telomerase mRNA (hTERT) in colon cancer. Int J Oncol 2002; 21: 4937.
  • 11
    Bechter OE, Eisterer W, Dlaska M, Kuhr T, Thaler J. CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia. Exp Hematol 2002; 30: 2633.
  • 12
    Guilleret I, Yan P, Grange F, Braunschweig R, Bosman FT, Benhattar J. Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer 2002; 101: 33541.
  • 13
    Xu D, Popov N, Hou M, Wang Q, Bjorkholm M, Gruber A, Menkel AR, Henriksson M. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci U S A 2001; 98: 382631.
  • 14
    Cong YS, Bacchetti S. Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J Biol Chem 2000; 275: 356658.
  • 15
    Hou M, Wang X, Popov N, Zhang A, Zhao X, Zhou R, Zetterberg A, Bjorkholm M, Henriksson M, Gruber A, Xu D. The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp Cell Res 2002; 274: 2534.
  • 16
    Liu JP. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 1999; 13: 2091104.
  • 17
    Szutorisz H, Palmqvist R, Roos G, Stenling R, Schorderet D, Reddel R, Lingnerm J Nabholz M. Rearrangements of minisatellites in the human telomerase reverse transcriptase gene are not correlated with its expression in colon carcinomas. Oncogene 2001; 20: 26005.
  • 18
    Zhang A, Zheng C, Lindvall C, Hou M, Ekedahl J, Lewensohn R, Yan Z, Yang X, Henriksson M, Blennow E, Nordenskjold M, Zetterberg A, et al. Frequent amplification of the telomerase reverse transcriptase gene in human tumors. Cancer Res 2000; 60: 62305.
  • 19
    Zhang A, Zheng C, Hou M, Lindvall C, Wallin KL, Angstrom T, Yang X, Hellstrom AC, Blennow E, Bjorkholm M, Zetterberg A, Gruber A, et al. Amplification of the telomerase reverse transcriptase (hTERT) gene in cervical carcinomas. Genes Chromosomes Cancer 2002; 34: 26975.
  • 20
    Fan X, Wang Y, Kratz J, Brat DJ, Robitaille Y, Moghrabi A, Perlman EJ, Dang CV, Burger PC, Eberhart CG. hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am J Pathol 2003; 162: 17639.
  • 21
    Norrback K-F, Dahlenborg K, Carlsson R, Roos G. Telomerase activation in normal B lymphocytes and Non-Hodgkin's lymphomas. Blood 1996; 88: 2229.
  • 22
    Norrback K-F, Enblad G, Erlanson M, Sundström C, Roos G. Telomerase activity in Hodgkin's disease. Blood 1998; 92: 56773.
  • 23
    Palmqvist R, Öberg Å, Bergström C, Rutegård JN, Zackrisson B, Stenling R. Systematic heterogeneity and prognostic significance of cell proliferation in colorectal cancer. Br J Cancer 1998; 77: 91725.
  • 24
    McKay JA, Douglas JJ, Ross VG, Curran S, Ahmed FY, Loane JF, Murray GI, McLeod HL. Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. Clin Cancer Res 2000; 6: 11138.
  • 25
    Vindelov LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983; 3: 3237.
  • 26
    Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 524857.
  • 27
    De Angelis PM, Clausen OP, Schjolberg A, Stokke T. Chromosomal gains and losses in primary colorectal carcinomas detected by CGH and their associations with tumour DNA ploidy, genotypes and phenotypes. Br J Cancer 1999; 80: 52635.
  • 28
    Aragane H, Sakakura C, Nakanishi M, Yasuoka R, Fujita Y, Taniguchi H, Hagiwara A, Yamaguchi T, Abe T, Inazawa J, Yamagishi H. Chromosomal aberrations in colorectal cancers and liver metastases analyzed by comparative genomic hybridization. Int J Cancer 2001; 94: 6239.
  • 29
    Platzer P, Upender MB, Wilson K, Willis J, Lutterbaugh J, Nosrati A, Willson JK, Mack D, Ried T, Markowi. Silence of chromosomal amplifications in colon cancer. Cancer Res 2002; 62: 11348.
  • 30
    Frei JV. Hereditary nonpolyposis colorectal cancer (Lynch syndrome II). Diploid malignancies with prolonged survival. Cancer 1992; 69: 110811.
  • 31
    Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P. p53 in colorectal cancer: Clinicopathological correlation and prognostic significance. Br J Cancer 1991; 63: 3179.
  • 32
    Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 93748.
  • 33
    Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70: 92335.
  • 34
    Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 6237.
  • 35
    Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, Cavalieri RJ, Boland CR. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 1993; 104: 153549.